

CLASSIFICATION: UNCLASSIFIED/  
ROUTINE  
R 141735Z JAN 26 MID180038529025U  
FM SECNAV WASHINGTON DC  
TO ALNAV  
INFO SECNAV WASHINGTON DC  
CNO WASHINGTON DC  
CMC WASHINGTON DC  
BT  
UNCLAS

ALNAV 003/26

MSGID/GENADMIN/SECNAV WASHINGTON DC/--/JAN//

SUBJ/PROHIBITION OF THE USE OF KRATOM, MITRAGYNINE AND 7- HYDROXYMITRAGYNINE PRODUCTS//

REF/A/USD-PR MEMORANDUM/15SEP25//  
REF/B/DOC/SECNAVINST/23APR19//  
REF/C/DOC/DODINST/06SEP23//

NARR/REF A IS UNDER SECRETARY OF DEFENSE FOR PERSONNEL AND READINESS MEMORANDUM, ADOPTION OF PUNITIVE GENERAL ORDERS OR REGULATIONS TO ADDRESS USE OF KRATOM, MITRAGYNINE AND 7- HYDROXYMITRAGYNINE PRODUCTS 15SEP25. REF B IS SECNAVINST 5300.28F, MILITARY SUBSTANCE ABUSE PREVENTION AND CONTROL. REF C IS DOD INSTRUCTION 6490.08, COMMAND NOTIFICATION REQUIREMENTS TO DISPEL STIGMAS IN PROVIDING MENTAL HEALTH CARE TO SERVICE MEMBERS.//

RMKS/1. Kratom is derived from the leaves of an indigenous Southeast Asian tree. The leaves contain mitragynine and 7-hydroxymitragynine, which have opioid and stimulant effects.

7-Hydroxymitragynine is significantly more potent than morphine and may also be synthesized or concentrated in a laboratory. These compounds may be sold in the form of leaves, capsules, gummies, edibles, shots, vapes, and other products.

2. The Food and Drug Administration has not federally regulated kratom, mitragynine, or 7-hydroxymitragynine. Unregulated products may contain labeling inaccuracies, such as the product ingredients or concentrations, resulting in increased health and safety risks.

3. Kratom, mitragynine, and 7-hydroxymitragynine use poses significant health risks including seizures, tachycardia, hepatotoxicity, hypertension, and death. Several countries and states have classified kratom as a controlled substance due to its high potential for misuse, and the Drug Enforcement Agency classified kratom as a Drug and Chemical of Concern.

4. Effective immediately, Sailors and Marines are prohibited from engaging in the use, possession, distribution, and/or manufacture of any substance, product, compound or item containing, or derived from, kratom, including but not limited to mitragynine or 7-hydroxymitragynine. This restriction applies to products that are naturally derived, semi-synthetic or synthetic, regardless of the substance's concentration, claimed or actual, and regardless of whether such product may lawfully be bought, sold, or used

under civilian law. Use means to inject, ingest, inhale, or otherwise introduce into the human body.

5. Protecting Service Member welfare and readiness is paramount to maintaining an effective fighting force.

Additionally, substance misuse by members of the Armed Forces is incompatible with military standards of good order, discipline, performance, and operational readiness. The prohibition on kratom, mitragynine, and 7-hydroxymitragynine underscores the Department's commitment to ensuring the health and readiness of the force, implements the direction from reference (a), and reinforces the Department's zero tolerance policy for drug misuse set forth in reference (b).

Service Members who fail to comply with this ALNAV are in violation of the Uniform Code of Military Justice (UCMJ), Article 92, Failure to Obey a Lawful General Order, and any other UCMJ articles that may apply. Violations may result in administrative and/or disciplinary action.

6. Sailors and Marines who use kratom, mitragynine, or 7-hydroxymitragynine or suspect they may have developed an addiction are strongly encouraged to voluntarily seek help.

The Navy's Substance Abuse Rehabilitation Program and Marine Corps Substance Assessment and Counseling Centers offer confidential services in accordance with reference (c) aimed at providing tailored support, referral, and treatment, as applicable.

7. This policy does not prohibit use: pursuant to legitimate law enforcement activities; by authorized personnel in the performance of medical duties; or use without knowledge that the product was made or derived from kratom, including products containing mitragynine or 7-hydroxymitragynine. However, an individual who consciously avoids knowledge of the presence of these substances is subject to the same criminal and/or administrative liability as one who has actual knowledge.

8. The Chief of Naval Operations and the Commandant of the Marine Corps will implement this policy.

9. The primary point of contact for this message is Ms. Brittany Wolf, Director, Drug Demand Reduction Program, who can be reached at (703) 614-7114 or via email at [brittany.m.wolf5.civ@us.navy.mil](mailto:brittany.m.wolf5.civ@us.navy.mil).

a. United States Marine Corps Commands may contact Ms. Carrie Knox at (703) 432-1359 or via email at [carrie.knox@usmc.mil](mailto:carrie.knox@usmc.mil).

b. United States Navy Commands may contact Ms. LaNorfeia Parker at (901) 874-4249 or via email at [lanorfeia.parker.civ@us.navy.mil](mailto:lanorfeia.parker.civ@us.navy.mil).

10. This ALNAV is effective immediately until superseded or cancelled, whichever comes first.

11. Released by the Honorable John C. Phelan, Secretary of the Navy.//

BT

#0001

NNNN

CLASSIFICATION: UNCLASSIFIED/